01672.HK
Ascletis Pharma Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 4.90
−6.04%Year over year
Reported trailing growth
- Revenue
- -59.9%
- EBITDA
- -62.0%
- EBIT
- -37.3%
- EPS
- —
- Free cash flow
- -60.3%
- Operating cash flow
- -60.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -45.1%
- EPS
- +24.4%
Three-year CAGR
- Revenue
- -66.5%
- EBITDA
- -21.5%
- EBIT
- -63.8%
- Net income
- -19.6%
- EPS
- -23.3%
- Free cash flow
- +3.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026